OMS302

DRUG4 trials

Sponsors

Omeros Corporation

Conditions

Cataract ExtractionCongenital CataractIntraocular Lens ReplacementUnilateral Cataract Extraction

Phase 1

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

CompletedNCT00721695

Omeros CorporationCataract Extraction

Start: 2008-05-31End: 2009-02-28Updated: 2014-07-18

Phase 3

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

CompletedNCT01454063

Omeros CorporationIntraocular Lens Replacement

Start: 2011-09-30End: 2012-03-31Updated: 2014-08-21

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

CompletedNCT01579565

Omeros CorporationIntraocular Lens Replacement

Start: 2012-04-30End: 2013-01-31Updated: 2017-06-14

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

CompletedNCT02132312

Omeros CorporationCongenital Cataract, Unilateral Cataract Extraction

Start: 2014-07-31End: 2016-09-12Updated: 2021-07-22